USPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
US Physical Therapy Inc is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock has some supportive fundamental and sentiment factors, but the technical setup is mixed and the latest analyst revisions are trending lower on price targets. Given the user's impatience and desire to act now, I would not call this an immediate buy; I would hold and wait for a cleaner entry or a stronger confirmation signal.
USPH is trading at 64.16, just above pivot support at 63.09 and below resistance at 65.18. Momentum is improving because the MACD histogram is positive and expanding, but RSI-6 at 57.64 is only neutral. The moving averages are still bearish with SMA_200 > SMA_20 > SMA_5, which means the broader trend remains weak. The short-term setup is mixed rather than decisively bullish, and the modeled price behavior also points to limited near-term upside with downside risk over the next month.
["Analysts still maintain positive ratings, including Outperform and Buy views.", "Jefferies expects organic growth acceleration and margin expansion from hospital alliances and improved Medicare pricing.", "The company recently beat revenue and EBITDA estimates, even though it missed consensus.", "MACD momentum is improving and currently positive."]
["Recent analyst price target cuts from $103 to $90 and from $113 to $98 show reduced upside expectations.", "Q1 was described as a mixed report with lower profitability expectations and higher net debt assumptions.", "No news catalysts in the last week.", "Options positioning is skewed bearish with a 2.72 put-call ratio.", "The technical trend remains bearish on moving averages, and historical pattern analysis suggests weakness over the next month."]
Latest quarter financial details were not fully available due to a data error, but the most recent quarter was described by analysts as mixed. Revenue and EBITDA were above the firm's internal estimates but below broader consensus, with adverse weather noted as a headwind. Profitability expectations were lowered and net debt was expected to be higher, so the latest quarter appears to show growth that is present but not yet translating into strong earnings momentum. The latest quarter season appears to be Q1.
Analyst sentiment remains constructive overall, but the trend is weakening. Barrington lowered its target to $90 from $103 while keeping Outperform, and Citizens cut its target to $98 from $113 while staying positive. Jefferies initiated/assumed coverage with a Buy rating and a $102 target. The pros view is that improved Medicare rates and hospital alliances could support growth and margins. The cons view is that profitability has softened, targets are being reduced, and the recent quarter was mixed.
